1-10 of 10
Rama Krishna Narla
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma

Lynda Groocock, Gauri Deb, Jinyi Zhu, Jim Gamez, Paola Castiglioni, Manuel Sanchez-Castillo, Justin Schumacher, Alicia Benitez Rondan, Diana Jankeel, Karla Martinez-Garcia, Scott Wood, Andy Christoforou, Carla Guarinos, Wei Zhang, Rama Krishna Narla, Christoph W. Zapf, Soraya Carrancio, Daniel W. Pierce, Mark Rolfe, Neil Bence, Antonia Lopez-Girona, Deborah S. Mortensen
Journal: Blood
Blood (2024) 144 (Supplement 1): 957.
https://doi.org/10.1182/blood-2024-210951
Published: 2024
Journal Articles

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Carmen Jimenez, Jose Francisco Lopez, Estela Garcia, Laura Diaz Regalado, Alejandro Panjkovich, Sophie Peng, Rama Krishna Narla, Noelia Purroy, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio
Journal: Blood
Blood (2024) 144 (Supplement 1): 1395.
https://doi.org/10.1182/blood-2024-210023
Published: 2024
Journal Articles

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez, Sophie Peng, Rama Krishna Narla, Joshua Baughman, Scott Wood, Jean Lu, Noelia Purroy, Gina Yanochko, Mark Nagy, Gang Lu, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio
Journal: Blood
Blood (2024) 144 (Supplement 1): 4142.
https://doi.org/10.1182/blood-2024-209924
Published: 2024
Journal Articles

Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Emily Rychak, Goldie Yuan Lam Lui, Cristhian Fimbres, Christine Kim Kang, Younguk Sun, Sophie Peng, Jingjing Deng, Sarah Franc, Eugene Ciccimaro, Kimberly Peacock, Minerva Tran, Andy Christoforou, Jinyi Zhu, Geraldine Polido, Barbra Pagarigan, Scott Johnson, Faye Wang, Paula Katavolos, Bonny Gaffney, Estela Garcia, France Landry, Fletcher Paddison, Petia Shipkova, Hannah Powers, Giorgio Tamò, August Dietrich, Soraya Carrancio, Radha Ramakrishnan, Karen Augustine, Rama Krishna Narla, Thomas Cummins, Mark Rolfe, Neil Bence, Antonia Lopez-Girona
Journal: Blood
Blood (2024) 144 (Supplement 1): 169.
https://doi.org/10.1182/blood-2024-203653
Published: 2024
Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce
Journal: Blood
Blood (2019) 134 (Supplement_1): 1815.
https://doi.org/10.1182/blood-2019-124345
Published: 2019
Journal Articles

Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)

Xiaofan Li, PhD, Cristina Abrahams, PhD, Millicent Embry, Abigail Yu, PhD, Jason Kahana, PhD, Michael Brown, Rama Krishna Narla, PhD, Leo Barnes, Eric Schwartz, PhD, John Boylan, PhD, James Zawada, PhD, Heather Stephenson, Maureen Bruhns, PhD, Stuart Bussell, PhD, Alexander Steiner, M.S., Adam Galan, PhD, Toni Kline, PhD, Alice Yam, PhD, Ryan Stafford, PhD, Heidi Hoffmann, PhD, Shannon Matheny, PhD, Venita DeAlmeida, PhD, Nicki Vasquez, PhD, Henry Heinsohn, Aaron Sato, PhD, Arturo Molina, MD MS, Trevor Hallam, PhD, Mark Lupher, Jr., PhD
Journal: Blood
Blood (2016) 128 (22): 464.
https://doi.org/10.1182/blood.V128.22.464.464
Published: 2016
Journal Articles

Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models

Cristina Abrahams, PhD, Xiaofan Li, PhD, Abigail Yu, PhD, Stellanie Krimm, Jason Kahana, PhD, Rama Krishna Narla, PhD, Eric Schwartz, PhD, John Boylan, PhD, Heidi Hoffmann, PhD, Alexander Steiner, M.S., James Zawada, PhD, Heather Stephenson, Maureen Bruhns, PhD, Venita DeAlmeida, PhD, Shannon Matheny, PhD, Stuart Bussell, PhD, Adam Galan, PhD, Toni Kline, PhD, Nicki Vasquez, PhD, Alice Yam, PhD, Ryan Stafford, PhD, Henry Heinsohn, Aaron Sato, PhD, Arturo Molina, MD MS, Trevor Hallam, PhD, Mark Lupher, Jr., PhD
Journal: Blood
Blood (2016) 128 (22): 4465.
https://doi.org/10.1182/blood.V128.22.4465.4465
Published: 2016
Journal Articles

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Patrick R. Hagner, Hon-Wah Man, Celia Fontanillo, Maria Wang, Suzana Couto, Mike Breider, Chad Bjorklund, Courtney G. Havens, Gang Lu, Emily Rychak, Heather Raymon, Rama Krishna Narla, Leo Barnes, Gody Khambatta, Hsiling Chiu, Jolanta Kosek, Jian Kang, Michael D. Amantangelo, Michelle Waldman, Antonia Lopez-Girona, Ti Cai, Michael Pourdehnad, Matthew Trotter, Thomas O. Daniel, Peter H. Schafer, Anke Klippel, Anjan Thakurta, Rajesh Chopra, Anita K. Gandhi
Journal: Blood
Blood (2015) 126 (6): 779–789.
https://doi.org/10.1182/blood-2015-02-628669
Published: 2015
Includes: Supplemental data
Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD
Journal: Blood
Blood (2014) 124 (21): 3035.
https://doi.org/10.1182/blood.V124.21.3035.3035
Published: 2014
Journal Articles

The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Emily Rychak, Ph.D., Derek Mendy, B.S., Karen Miller, B.S., Jim Leisten, B.S., Rama Krishna Narla, Ph.D., Heather K Raymon, Ph.D., Rajesh Chopra, M.D., Ph.D., Antonia Lopez-Girona, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 3160.
https://doi.org/10.1182/blood.V122.21.3160.3160
Published: 2013